ZNTL Straddle Strategy
ZNTL (Zentalis Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.
ZNTL (Zentalis Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $303.6M, a beta of 2.00 versus the broader market, a 52-week range of 1.13-6.95, average daily share volume of 1.9M, a public-listing history dating back to 2020, approximately 166 full-time employees. These structural characteristics shape how ZNTL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.00 indicates ZNTL has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a straddle on ZNTL?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current ZNTL snapshot
As of May 15, 2026, spot at $4.04, ATM IV 161.00%, IV rank 40.03%, expected move 46.16%. The straddle on ZNTL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on ZNTL specifically: ZNTL IV at 161.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 46.16% (roughly $1.86 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ZNTL expiries trade a higher absolute premium for lower per-day decay. Position sizing on ZNTL should anchor to the underlying notional of $4.04 per share and to the trader's directional view on ZNTL stock.
ZNTL straddle setup
The ZNTL straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ZNTL near $4.04, the first option leg uses a $4.04 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ZNTL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ZNTL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.04 | N/A |
| Buy 1 | Put | $4.04 | N/A |
ZNTL straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
ZNTL straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on ZNTL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on ZNTL
Straddles on ZNTL are pure-volatility plays that profit from large moves in either direction; traders typically buy ZNTL straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
ZNTL thesis for this straddle
The market-implied 1-standard-deviation range for ZNTL extends from approximately $2.18 on the downside to $5.90 on the upside. A ZNTL long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ZNTL IV rank near 40.03% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on ZNTL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ZNTL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ZNTL-specific events.
ZNTL straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ZNTL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ZNTL alongside the broader basket even when ZNTL-specific fundamentals are unchanged. Always rebuild the position from current ZNTL chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on ZNTL?
- A straddle on ZNTL is the straddle strategy applied to ZNTL (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ZNTL stock trading near $4.04, the strikes shown on this page are snapped to the nearest listed ZNTL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ZNTL straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ZNTL straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 161.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ZNTL straddle?
- The breakeven for the ZNTL straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ZNTL market-implied 1-standard-deviation expected move is approximately 46.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on ZNTL?
- Straddles on ZNTL are pure-volatility plays that profit from large moves in either direction; traders typically buy ZNTL straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current ZNTL implied volatility affect this straddle?
- ZNTL ATM IV is at 161.00% with IV rank near 40.03%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.